Komori
Takara Bio (4974) · RiskRestated

Risk of Litigation, Patent Infringement and Third-Party Disputes

First written in FY2023. 2 of 4 entries say "Restated". Latest entry: FY2025-H1.

4entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2023 – FY2024-Q3MitigatedFY20242023: 120232024: 32024
Same theme, other companies
Risk of Infringing Third-Party Intellectual Property RightsA theme 465 companies write about · 468 as a headwind · 1 as a tailwind
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 197 companies compared. The sentences above are computed from all 197.Comparing 200 of the theme's 469 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025-H1RestatedAnnual report

    「During the current interim consolidated accounting period, there were no new business or other risks, nor any material changes to the business or other risks described in the securities report for the previous fiscal year.」

    訴訟・特許権侵害・第三者紛争リスクについて、新規発生または重要な変更はないとしている。
  2. FY2024MitigatedAnnual report

    「このようなリスクを踏まえ、当社グループでは、国内外の事業活動の遂行に際し、内部統制の充実やコンプライアンスの強化に努めております。また、当社グループでは、事業展開にあたり知的財産権に関する調査を適宜実施しております。」

    訴訟・特許権侵害・第三者紛争リスクに対し、内部統制、コンプライアンス強化、知的財産権調査を対応策として明示した。
  3. FY2024-Q3RestatedAnnual report

    「During the nine-month period ended [the current third quarter], there were no newly arising business or other risks, nor any material changes to the business and other risks described in the Annual Securities Report for the prior fiscal year.」

    訴訟・特許権侵害・第三者紛争リスクについて、新規発生または重要な変更はないとしている。
  4. FY2023First statedAnnual report

    「For an R&D-driven company such as the Group, it is difficult to completely avoid patent infringement issues. If an intellectual property infringement issue arises, the Group may face claims for damages, injunctions or royalty payments, potentially affecting its business strategy and financial results.」

    First separately detailed the possibility of damages, injunction and royalty claims arising from patent infringement, in addition to general third-party litigation.
Moved together

None of this company's other threads moved the same way in the same document twice or more.

When this could move next
No upcoming earnings preview for Takara Bio yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Risk of Litigation, Patent Infringement and Third-Party Disputes | TAKARA BIO INC. (4974) | Komori